Repatha Access in 2026: A Provider Briefing

If you prescribe Repatha (evolocumab), you're almost certainly fielding patient questions about access, cost, and coverage. While the PCSK9 inhibitor landscape has matured significantly since Repatha's 2015 launch, the practical challenges of getting patients their medication remain a persistent clinical concern — especially for the patients who need it most.

This briefing covers the current availability landscape, prior authorization strategies, cost considerations, and tools to streamline your practice's approach to PCSK9 inhibitor access.

Complete Timeline: How We Got Here

August 2015: FDA approves Repatha (evolocumab) for primary hyperlipidemia and homozygous familial hypercholesterolemia. Initial list price set at approximately $14,100 per year.

2015-2017: Widespread insurance pushback. Prior authorization denial rates for PCSK9 inhibitors reach 60-80% across many payers. Step therapy and LDL threshold requirements severely restrict access.

December 2017: FDA approves cardiovascular outcomes indication based on FOURIER trial data — Repatha reduced cardiovascular events by 15% vs. placebo in patients with established ASCVD.

October 2018: Amgen announces net price reduction of approximately 60%, bringing the effective annual cost to roughly $5,850. This was a landmark move intended to improve payer acceptance.

2019-2023: Prior authorization approval rates gradually improve as payers incorporate FOURIER data and respond to the price reduction. Coverage criteria begin distinguishing between ASCVD and primary prevention indications.

2024-2026: Leqvio (inclisiran) enters the market and gains formulary placement, adding another PCSK9-targeting option. Some payers begin requiring Leqvio trial before Repatha. Biosimilar development progresses but no US approvals yet.

What the Current Access Landscape Means for Your Prescribing Practice

Prior Authorization Complexity

Prior authorization remains the primary access barrier for Repatha in 2026. However, requirements vary significantly by payer and indication:

• ASCVD patients: Approval rates have improved substantially. Most major payers now approve PCSK9 inhibitors for patients with established ASCVD on maximally tolerated statin + ezetimibe with LDL-C ≥70 mg/dL. Some plans have lowered thresholds further
• Heterozygous FH: Coverage typically requires documented FH diagnosis (clinical criteria or genetic testing) plus statin + ezetimibe failure with LDL-C above plan-specific thresholds (often ≥100 mg/dL)
• Homozygous FH: Generally the most straightforward approval — genetic or clinical documentation of HoFH usually suffices
• Primary prevention: Remains the most challenging indication for PCSK9 inhibitor approval. Many payers do not cover Repatha for primary prevention patients without FH

Formulary Considerations

Some payers now prefer one PCSK9 inhibitor over the other. Key patterns:

• Repatha preferred: Plans contracted with Amgen may require Repatha specifically
• Praluent preferred: Plans contracted with Regeneron/Sanofi may require Praluent as first-line PCSK9 inhibitor
• Leqvio step therapy: A growing number of payers are positioning Leqvio before traditional PCSK9 inhibitors, particularly for patients comfortable with in-office administration

The Real-World Availability Picture

Supply Chain Status

Repatha's supply chain is stable. Amgen's manufacturing capacity is adequate, and the medication is not on the FDA shortage list. The access challenges your patients face are downstream: specialty pharmacy distribution, insurance processing, and cost.

Specialty Pharmacy Distribution

Repatha flows through a limited specialty pharmacy network. Most patients receive it via their insurer's preferred specialty pharmacy (CVS Specialty, Accredo, AllianceRx Walgreens, OptumRx Specialty). This means:

• Prescriptions sent to retail pharmacies are typically redirected to specialty channels
• New patient setup at a specialty pharmacy can take 3-7 business days
• Cold-chain shipping adds logistical complexity but is well-established

Dose-Specific Considerations

Both dosing options (140 mg every 2 weeks and 420 mg monthly) are generally available through specialty pharmacies. The monthly 420 mg dose uses either three consecutive 140 mg injections or the Pushtronex on-body infusor — ensure patients understand their options.

Cost and Access: The Numbers Your Patients Are Seeing

Pricing

• List price: ~$5,850/year (post-2018 Amgen net price reduction)
• Cash/retail price: $500–$700 per monthly supply
• With Amgen copay card (commercial): As low as $5/month
• Medicare Part D: Variable; patients in coverage gap face significant costs. Copay card not available for government insurance

Manufacturer Programs

• Repatha Copay Card: Commercial insurance patients pay as low as $5/month. Enrollment at repatha.com
• Amgen Safety Net Foundation: Free medication for qualifying uninsured/underinsured patients (income ≤400% FPL)
• Amgen FIRST STEP: Temporary free medication during insurance access delays — valuable for keeping patients on therapy during PA processing

Impact on Adherence

Cost remains a significant driver of PCSK9 inhibitor non-adherence. Studies have shown that approximately 30-50% of patients discontinue PCSK9 inhibitors within the first year, with cost and insurance barriers cited as primary reasons. Proactive enrollment in copay assistance at the point of prescribing is critical.

Tools and Resources for Your Practice

• Medfinder Provider Portal — search pharmacy availability on behalf of patients, identify specialty pharmacies with stock
• FDA Drug Shortage Database — monitor for any supply disruptions (currently no Repatha shortage listed)
• Amgen Reimbursement Support: 1-844-REPATHA — assists with PA submissions, appeals, and benefit verification
• CoverMyMeds: Electronic prior authorization platform — many payers accept ePA for PCSK9 inhibitors

Looking Ahead

Biosimilar Pipeline

Several Repatha biosimilars are in development, though none have received FDA approval as of early 2026. Biosimilar competition could reduce costs and potentially shift some prescribing from specialty to retail pharmacy channels.

Evolving Payer Criteria

Expect continued evolution of PA criteria as cardiovascular outcomes data matures and Leqvio adoption grows. Some payers may further simplify approval for high-risk ASCVD patients.

New Guidelines

Updated lipid management guidelines continue to emphasize earlier and more aggressive LDL lowering in high-risk patients, which may support broader PCSK9 inhibitor coverage over time.

Final Thoughts

The Repatha access story in 2026 is one of improving but still imperfect coverage. The supply is there; the barriers are administrative and financial. As prescribers, the most impactful steps we can take are:

1. Submit thorough PA documentation upfront — include all required elements to minimize back-and-forth
2. Enroll patients in the copay card at the point of prescribing — don't let cost be a surprise at the pharmacy
3. Know your plan-specific requirements — some payers have specific LDL thresholds, step therapy sequences, or preferred PCSK9 agents
4. Use the Medfinder provider portal to help patients navigate pharmacy access
5. Have Leqvio in your toolkit as an alternative that bypasses some specialty pharmacy and adherence barriers

For the patient-facing perspective on these issues, share our Repatha 2026 patient update with your patients. For practical access guidance, see our provider guide to helping patients find Repatha.